glutamic acid has been researched along with Urinary Bladder Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anzengruber, M; Apfelthaler, C; Gabor, F; Wirth, M | 1 |
| Hristova, K; Li, E; You, M | 1 |
| Taylor, JA; Terry, PD; Umbach, DM | 1 |
| Amorós, A; Carrato, A; Hernández, S; Kogevinas, M; Lloreta, J; López-Knowles, E; Malats, N; Real, FX; Serra, C; Tardón, A | 1 |
4 other study(ies) available for glutamic acid and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
Poly - (l) - glutamic acid drug delivery system for the intravesical therapy of bladder cancer using WGA as targeting moiety.
Topics: Administration, Intravesical; Cell Line, Tumor; Drug Delivery Systems; Glutamic Acid; Humans; Lectins; Pharmaceutical Preparations; Polymers; Urinary Bladder; Urinary Bladder Neoplasms; Urothelium; Wheat Germ Agglutinins | 2017 |
FGFR3 dimer stabilization due to a single amino acid pathogenic mutation.
Topics: Alanine; Amino Acid Sequence; Amino Acid Substitution; Cell Membrane; Craniofacial Dysostosis; Dimerization; Electrophoresis, Polyacrylamide Gel; Fluorescence Resonance Energy Transfer; Glutamic Acid; Humans; Liposomes; Models, Molecular; Molecular Sequence Data; Mutation; Protein Structure, Secondary; Protein Structure, Tertiary; Receptor, Fibroblast Growth Factor, Type 3; Signal Transduction; Thermodynamics; Urinary Bladder Neoplasms | 2006 |
APE1 genotype and risk of bladder cancer: evidence for effect modification by smoking.
Topics: Aged; Aspartic Acid; Case-Control Studies; DNA Damage; DNA Repair; DNA-(Apurinic or Apyrimidinic Site) Lyase; Female; Genotype; Glutamic Acid; Guanine; Humans; Male; Mass Spectrometry; Middle Aged; North Carolina; Polymorphism, Genetic; Risk Assessment; Smoking; Thymine; Urinary Bladder Neoplasms | 2006 |
Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Cysteine; Female; Glutamic Acid; Glycine; Humans; Leucine; Male; Middle Aged; Multivariate Analysis; Mutation; Phenylalanine; Polymerase Chain Reaction; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Prospective Studies; Receptor, Fibroblast Growth Factor, Type 3; Sequence Analysis, DNA; Serine; Tyrosine; Urinary Bladder Neoplasms | 2006 |